$FGEN News
Last published 8mo ago
- 8mo agoFGENKYNBKyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireSAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close.
- 8mo agoFGENKYNBKyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026GlobeNewswireFG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a
- 8mo agoFGENKYNBKyntra Bio to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), today announced that the company's management will participate in the following investor conferences:
- 10mo agoFGENFibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and MomentumGlobeNewswireName change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq under the trading
- 11mo agoFGENRoxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug AdministrationGlobeNewswireCompany is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Office of Orphan Products
- 11mo agoFGENFibroGen to Present at the Oppenheimer Movers in Rare Disease SummitGlobeNewswireSAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December
- 1y agoFGENFibroGen Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireCompleted the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic
- 1y agoFGENFibroGen to Report Third Quarter 2025 Financial ResultsGlobeNewswireSAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call
- 1y agoFGENFibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate CancerGlobeNewswireFG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to
- 1y agoFGENFibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 MillionGlobeNewswireTotal consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidanceSuccessfully repaid term loan to Morgan Stanley Tactical Value, further
- 1y agoFGENFibroGen to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireSAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being
- 1y agoFGENFibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market RegulationGlobeNewswireSale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the China State Administration for Market Regulation
- 1y agoFGENFibroGen, Inc. (FGEN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoFGENFibroGen Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireTotal consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be
- 1y agoFGENFibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic SyndromesGlobeNewswireFibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and
- 1y agoFGENFibroGen to Report Second Quarter 2025 Financial ResultsGlobeNewswireSAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference
- 1y agoFGENFibroGen Announces 1-for-25 Reverse Stock SplitGlobeNewswireSAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock
- 1y agoFGENFibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of DirectorsGlobeNewswireSAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized
- 1y agoFGENFibroGen Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireTotal consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be
- 1y agoFGENFibroGen to Report First Quarter 2025 Financial ResultsGlobeNewswireSAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on
- 1y agoFGENFibroGen to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.
- 1y agoFGENFibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical OncologyGlobeNewswireFG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 monotherapy dose optimization study of FG-3246 in
- 1y agoFGENFibroGen Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireAnnounced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027
- 1y agoFGENFibroGen to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireSAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a
- 1y agoFGENFibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 MillionGlobeNewswirePurchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan
- 1y agoFGENFibroGen Appoints David DeLucia as Chief Financial OfficerGlobeNewswireSAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously
- 1y agoFGENFibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call TranscriptEarnings Call Transcripts
- 2y agoFGENFibroGen Reports Third Quarter 2024 Financial ResultsGlobeNewswireTopline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic
- 2y agoFGENFibroGen to Report Third Quarter 2024 Financial ResultsGlobeNewswireSAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference
- 2y agoFGENFibroGen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireSAN FRANCISCO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being
- 2y agoFGENFibroGen, Inc. (FGEN) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoFGENFibroGen Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireCompany implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75%Focus R&D investment on
- 2y agoFGENFibroGen to Report Second Quarter 2024 Financial ResultsGlobeNewswireSAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also conduct a conference
- 2y agoFGENFibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate UpdateGlobeNewswirePamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as
- 2y agoFGENFibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024GlobeNewswireSAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To
- 2y agoONCYVSTMCADLFGEN+1Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking TreatmentsPR NewswireAfter looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may ...
- 2y agoFGENFibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical TrialsGlobeNewswireFibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175,
- 2y agoFGENFibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid TumorsGlobeNewswireThe safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumorsPlan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today
- 2y agoONCYVSTMCTMXBNTX+1Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival RatesPR NewswireUSA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...
- 2y agoFGENFibroGen to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewswireSAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global
- 2y agoFGENFibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual MeetingGlobeNewswireFG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patientsFG-3246 demonstrated an acceptable safety profile; adverse events
- 2y agoFGENFibroGen to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the company's management will participate in the following investor conferences: Bank of America Health Care
- 2y agoFGENFibroGen, Inc. (FGEN) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoFGENFibroGen Reports First Quarter 2024 Financial ResultsGlobeNewswireTopline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024Topline data from LAPIS Phase 3 study in locally advanced
- 2y agoFGENFibroGen to Report First Quarter 2024 Financial ResultsGlobeNewswireSAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on
- 2y agoFGENFibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual MeetingGlobeNewswireSAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in
- 2y agoFGENFibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerGlobeNewswireFG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression
- 2y agoFGENFibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireSAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual
- 2y agoFGENFibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerGlobeNewswireSAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as
- 2y agoFGENFibroGen, Inc. (FGEN) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts